DUBLIN, March 31, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference in Las Vegas on ...

Analyses from Randomized Controlled Trials Further Support the Target Engagement and Safety Profile of Ampreloxetine in Neurodegenerative Disease< ...

The partnership integrates advanced AI-driven analytics and clinical trial solutions, empowering biopharma companies to accelerate drug development and deliver targeted therapies faster. BETHESDA ...

DUBLIN, March 31, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference in Las Vegas on ...

Quantum BioPharma (QNTM) announced that the reconsideration motion by Dr. Raza Bokhari at the Court of Appeal, CoA, for Ontario was dismissed ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Avidity Biosciences (RNA – Research Report), ...

Shares of Mereo BioPharma Group stock opened at $2.30 on Thursday. The firm has a 50-day moving average of $2.72 and a 200-day moving average of $3.49. Mereo BioPharma Group has a 52-week low of ...

Mereo BioPharma Group (NASDAQ:MREO – Get Free Report)‘s stock had its “overweight” rating restated by stock analysts at Cantor Fitzgerald in a report released on Tuesday,Benzinga reports.

As of March 19, 2025, the average one-year price target for Mereo BioPharma Group plc - Depositary Receipt is $7.48/share. The forecasts range from a low of $5.76 to a high of $10.50.

Mereo BioPharma Group plc - Sponsored ADR (MREO) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in ...